retatrutide ly3437943 triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept What Is Retatrutide? The Triple

Youve likely heard about the incredible results of GLP-1 (glucagon-like peptide-1) medications, such as semaglutide, liraglutide, and tirzepatide, for

However, no direct link has been found between GLP-1R agonists and higher pulmonary aspiration risk

This is a huge market

It is not approved yet, but the data is starting to demand attention

We explore the underlying biological mechanisms, summarize clinical trial evidence, and highlight emerging applications in non-diabetic populations

this finding should be interpreted cautiously given the retrospective design, active and non-inert comparator, and likelihood of residual confounding